August 10, 2021
Article
Ten quiz questions to assess your knowledge on common multiple sclerosis treatments.
August 05, 2021
Erenumab was found to have a sustained efficacy as a monotherapy treatment for episodic migraine that was found to not respond to 2 to 4 prior preventive treatments.
Although there was a numerical difference between the mean number of new or newly enlarging T2 hyperintense lesions at week 72 of 0.05 (Q4W) and 0.20 (Q6W), this difference was not clinically meaningful in the context of the full data, according to the investigators.
August 04, 2021
Donanemab induced rapid amyloid plaque reduction at 24 weeks in patients with early symptomatic Alzheimer disease, with the most rapid clearance in patients with the most severe plaque burden at baseline.
July 23, 2021
Video
Because there are no other available treatment options, Pamela Spicer said the approval of aducanumab gives much-needed hope to patients with Alzheimer disease and their families.
July 22, 2021
This recurring condition can require more firepower than OTC pain medications offer.
Although she said it is unlikely that the FDA will retract the approval, prescribers could be reluctant to administer aducanumab to patients.
Patients treated with berubicin in clinical trials appeared to demonstrate positive responses, including 1 durable complete response in a phase 1 human clinical trial.
Advice to community pharmacists and patients who suffer from migraine on strategies that can improve quality of life and be used to navigate the care continuum.
Red flags that would prompt a pharmacist to refer a patient with migraine to be evaluated by a physician.
